Responsiveness to checkpoint inhibitors is the key to successful cancer therapy, and ICI efficacy is affected by many factors, such as tumor genomic variability, host germline genetics, and the microbiome or PD-L1 expression levels [107]. This evidence concerns the gene CD274 and cancer.